Publications by authors named "Rhoda Masonga"
Article Synopsis
- Vaccine safety and immunogenicity data are crucial for making informed decisions in countries where both HIV and typhoid are prevalent, specifically focusing on HIV-exposed uninfected (HEU) children.
- In a study involving Malawian infants, HEU and HIV unexposed uninfected (HUU) participants received the Vi-tetanus toxoid conjugate vaccine (Vi-TT) at different ages, with safety and immune response monitored after vaccination.
- Results showed that the vaccine was generally safe with mild adverse events, and both HEU and HUU children had strong immune responses, indicating that a single dose of Vi-TT could be effectively introduced in HIV-endemic regions.
Background: Sulfadoxine-pyrimethamine resistance threatens efficacy of intermittent preventive treatment of malaria during pregnancy, and alternative regimens need to be identified. With the return of chloroquine efficacy in southern Africa, we postulated that chloroquine either as an intermittent therapy or as weekly chemoprophylaxis would be more efficacious than intermittent sulfadoxine-pyrimethamine for prevention of malaria in pregnancy and associated maternal and newborn adverse outcomes.
Methods: We did an open-label, single-centre, randomised controlled trial at Ndirande Health Centre, Blantyre, in southern Malawi.
Background: The predominance of chloroquine-susceptible falciparum malaria in Malawi more than a decade after chloroquine's withdrawal permits contemplation of re-introducing chloroquine for targeted uses. We aimed to compare the ability of different partner drugs to preserve chloroquine efficacy and prevent the re-emergence of resistance.
Methodology/principal Findings: Children with uncomplicated malaria were enrolled at a government health center in Blantyre, Malawi.
Background: In 1993, Malawi became the first country in Africa to replace chloroquine with the combination of sulfadoxine and pyrimethamine for the treatment of malaria. At that time, the clinical efficacy of chloroquine was less than 50%. The molecular marker of chloroquine-resistant falciparum malaria subsequently declined in prevalence and was undetectable by 2001, suggesting that chloroquine might once again be effective in Malawi.
View Article and Find Full Text PDF